Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

OPNT

Opiant Pharmaceuticals (OPNT)

Opiant Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:OPNT
DatumZeitQuelleÜberschriftSymbolFirma
09/01/202323h15Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
09/01/202323h12Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
09/01/202323h10Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
05/01/202323h08Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
05/01/202323h04Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
05/01/202322h52Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
04/01/202322h21Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
21/12/202222h56Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (preliminary) (prem14a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
07/12/202216h27Edgar (US Regulatory)Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
22/11/202222h01GlobeNewswire Inc.Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid OverdoseNASDAQ:OPNTOpiant Pharmaceuticals Inc
15/11/202222h32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:OPNTOpiant Pharmaceuticals Inc
15/11/202212h10Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
15/11/202212h01Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
14/11/202222h25Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:OPNTOpiant Pharmaceuticals Inc
14/11/202210h26TipRanksHow Will Indivior’s $145M Purchase of Opiant Boost the Stock?NASDAQ:OPNTOpiant Pharmaceuticals Inc
14/11/202208h13GlobeNewswire Inc.Opiant Pharmaceuticals Announces Third Quarter 2022 Financial ResultsNASDAQ:OPNTOpiant Pharmaceuticals Inc
14/11/202208h12GlobeNewswire Inc.Indivior PLC to Acquire Opiant PharmaceuticalsNASDAQ:OPNTOpiant Pharmaceuticals Inc
14/11/202208h10PR Newswire (US)Indivior To Acquire Opiant PharmaceuticalsNASDAQ:OPNTOpiant Pharmaceuticals Inc
14/11/202208h10PR Newswire (US)Indivior To Acquire Opiant PharmaceuticalsNASDAQ:OPNTOpiant Pharmaceuticals Inc
27/10/202222h05GlobeNewswire Inc.Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022NASDAQ:OPNTOpiant Pharmaceuticals Inc
06/10/202214h01GlobeNewswire Inc.Opiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use DisorderNASDAQ:OPNTOpiant Pharmaceuticals Inc
22/08/202222h05GlobeNewswire Inc.Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis SyndromeNASDAQ:OPNTOpiant Pharmaceuticals Inc
12/08/202213h30PR Newswire (US)MindMed Strengthens Board with Appointment of Two New Independent DirectorsNASDAQ:OPNTOpiant Pharmaceuticals Inc
12/08/202213h30PR Newswire (Canada)MindMed Strengthens Board with Appointment of Two New Independent DirectorsNASDAQ:OPNTOpiant Pharmaceuticals Inc
11/08/202222h11Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:OPNTOpiant Pharmaceuticals Inc
11/08/202222h09Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:OPNTOpiant Pharmaceuticals Inc
11/08/202222h05GlobeNewswire Inc.Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate UpdateNASDAQ:OPNTOpiant Pharmaceuticals Inc
08/08/202222h05GlobeNewswire Inc.Opiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal NalmefeneNASDAQ:OPNTOpiant Pharmaceuticals Inc
02/08/202222h05GlobeNewswire Inc.Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent With Claims Covering OPNT003 for the Treatment of Opioid OverdoseNASDAQ:OPNTOpiant Pharmaceuticals Inc
01/08/202222h05GlobeNewswire Inc.Opiant Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022NASDAQ:OPNTOpiant Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:OPNT

Kürzlich von Ihnen besucht

Delayed Upgrade Clock